Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Vinorelbine With or Without Inetetamab in HER2+ MBC
NCT04963595Phase 2Unknown
- Start
- Aug 2021
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of inetetamab in HER2-positive breast cancer. Status: unknown.
02
Drugs
inetetamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04963595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963595.